327 related articles for article (PubMed ID: 28103831)
1. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.
Ziemssen F; Feltgen N; Holz FG; Guthoff R; Ringwald A; Bertelmann T; Wiedon A; Korb C;
BMC Ophthalmol; 2017 Jan; 17(1):7. PubMed ID: 28103831
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
3. Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.
Bertelmann T; Feltgen N; Scheffler M; Hufenbach U; Wiedon A; Wilhelm H; Ziemssen F
Health Qual Life Outcomes; 2016 Sep; 14(1):132. PubMed ID: 27644469
[TBL] [Abstract][Full Text] [Related]
4. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
[TBL] [Abstract][Full Text] [Related]
5. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
[TBL] [Abstract][Full Text] [Related]
6. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.
Volkmann I; Knoll K; Wiezorrek M; Greb O; Framme C
BMC Ophthalmol; 2020 Mar; 20(1):122. PubMed ID: 32228517
[TBL] [Abstract][Full Text] [Related]
7. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Holekamp N; Gentile B; Giocanti-Aurégan A; García-Layana A; Peto T; Viola F; Kertes PJ; Mirt M; Kotecha A; Lambert J; Lewis HB; Chi GC
Ophthalmic Res; 2024; 67(1):311-321. PubMed ID: 38679018
[TBL] [Abstract][Full Text] [Related]
8. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
9. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
10. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal.
Vaz-Pereira S; Marques IP; Matias J; Mira F; Ribeiro L; Flores R
Eur J Ophthalmol; 2017 Nov; 27(6):756-761. PubMed ID: 28315518
[TBL] [Abstract][Full Text] [Related]
12. Long-term dynamic changes and influencing factors of corneal morphology after multiple intravitreal injections of anti-VEGF drugs.
Qi Y; Li C; Ye S; Zhang Z; Li S; Zhang L
Medicine (Baltimore); 2024 Apr; 103(17):e37937. PubMed ID: 38669379
[TBL] [Abstract][Full Text] [Related]
13. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
Ciulla T; Pollack JS; Williams DF
Br J Ophthalmol; 2021 Dec; 105(12):1696-1704. PubMed ID: 33055088
[TBL] [Abstract][Full Text] [Related]
14. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
16. Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.
Voutsas NT; Papageorgiou E; Tantou A; Dimitriou VA; Tsironi EE; Kotoula M
Int Ophthalmol; 2022 Sep; 42(9):2673-2684. PubMed ID: 35416615
[TBL] [Abstract][Full Text] [Related]
17. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
18. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
[TBL] [Abstract][Full Text] [Related]
20. LESS IS MORE: Reducing Injections and Optimizing Vision With Anti-VEGF Therapy for nAMD, DR, and DME.
Retina; 2024 May; 44(5S):S1-S16. PubMed ID: 38739858
[No Abstract] [Full Text] [Related]
[Next] [New Search]
